-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the performance of major traditional Chinese medicine companies in 2021 has basically been announc.
According to industry statistics, 68 traditional Chinese medicine companies will achieve a total revenue of 32405 billion yuan in 2021, a year-on-year increase of about
The net profit attributable to the parent was 3202 billion yu.
Companies with strong profitability such as ST Kangmei, Qizheng Tibetan Medicine, Xinguang Pharmaceutical, Kangenbei,e.
However, from the perspective of research and development, as the core competitiveness of the sustainable development of pharmaceutical companies, the strength of traditional Chinese medicine companies is still insufficient in this rega.
Only four traditional Chinese medicine companies account for more than 20% of the research and development personnel, namely Shanghai Kaibao, Zhongsheng Pharmaceutical, Tailong Pharmaceutical and Huashen Technolo.
Among them, Shanghai Kaibao's research and development expenses in 2021 will be 73196 million yuan, a year-on-year increase of 317%, mainly due to the increase in investment in research and development activiti.
In 2021, the company has 450 R&D personn.
Although it has changed by -26% compared with the previous year, the proportion will reach 342%, exceeding 266% of the previous ye.
The company will continue to promote the process of research and development projects in 202 First, it will continue to promote the secondary development of its main product Tanreqing and the research and development progress of a series of varieties and products under research; Jointly develop new products in the direction of chiral materials used in medical devices and pharmaceuticals and other related fields, and deepen the company's industry-university-research cooperati.
According to public information, Shanghai Kaibao is a comprehensive pharmaceutical enterprise mainly engaged in the research and development, production and sales of modern Chinese medicin.
It is a national demonstration project base for high-tech industrialization of modern Chinese medicin.
Demonstration enterprise, Shanghai smart facto.
The 2021 annual report shows that the company has always adhered to the road of scientific and technological innovation that combines production, education and resear.
It has two platforms, the Shanghai Enterprise Technology Center and the Academician Expert Workstati.
While continuously improving the level of independent research and development, it has been jointly established with the Medical Experiment Center of the Chinese Academy of Chinese Medical Scienc.
Academician Workstation, and Shanghai Jiaotong University jointly build a biomaterials joint R&D center to build a high-tech platform with strong R&D and production capabilities for rapid transformation of results; at the same time, the company's "Modern Chinese Medicine Product Construction Project R&D Building" is built for future scientific researche.
The introduction and research and development of new products provide basic guarantees, and have a positive role in promoting the company's implementation of innovation and developme.
Zhongsheng Pharmaceutical's R&D expenses in 2021 will be 136 million yuan, a year-on-year increase of 23
During the reporting period, there were 450 R&D personnel, a slight increase of 45% over the previous ye.
The number of R&D personnel in 2021 accounted for 291%, compared with 276% of the previous ye.
has declin.
It is reported that the company has established a multi-mode virtuous cycle of R&D ecosystem, built a R&D model based on independent R&D and effectively supplemented by cooperative R&D, to meet the unmet major clinical needs as the guide, supplemented by product introduction, strategic investment, industrial Mergers and acquisitions, joint ventures and joint development and other forms to achieve synergy between production and research, mutual benefit and win-win situati.
Focusing on the research and development of innovative drugs, the company accurately determines the research and development direction, scientifically and rigorously establishes projects, and integrates internal and external professional resources to implement developme.
The company has established a well-trained and strong executive R&D team covering a complete chain from project initiation, chemical synthesis, biological evaluation, analytical methodology development, formulation research, and drug clinical research, while making appropriate use of social CRO resources , Guarantee quality, quantity, and progress on time, and established a good project management mechani.
The company has established close scientific research cooperation relationships with universities and scientific research institutes such as Sun Yat-sen University, Sichuan University, and National Respiratory Disease Clinical Research Center, and has carried out in-depth industry-university-research cooperation in personnel training, scientific research achievement transformation, and technical suppo.
The company provides external expert think tank support, and constantly transforms socialized scientific research strength into the company's innovation pow.
According to the data, the company is an enterprise integrating drug research and development, production and sales based on ophthalmology, cardiovascular and cerebrovascular, respiratory, digestive and other therapeutic fiel.
In addition, Tailong Pharmaceutical will have 473 R&D personnel in 2021, accounting for 241% of the company's total; Huashen Technology will have 137 R&D personnel in 2021, accounting for 217% of the company's tot.
In general, the proportion of R&D personnel in the total number of Chinese medicine companies still needs to be improved, and the R&D efforts also need to be increased in order to improve the company's own core competitiveness and innovation capabilities and embrace the market opportunities brought about by favorable polici.
Click to enter the exhibition page
According to industry statistics, 68 traditional Chinese medicine companies will achieve a total revenue of 32405 billion yuan in 2021, a year-on-year increase of about
The net profit attributable to the parent was 3202 billion yu.
Companies with strong profitability such as ST Kangmei, Qizheng Tibetan Medicine, Xinguang Pharmaceutical, Kangenbei,e.
However, from the perspective of research and development, as the core competitiveness of the sustainable development of pharmaceutical companies, the strength of traditional Chinese medicine companies is still insufficient in this rega.
Only four traditional Chinese medicine companies account for more than 20% of the research and development personnel, namely Shanghai Kaibao, Zhongsheng Pharmaceutical, Tailong Pharmaceutical and Huashen Technolo.
Among them, Shanghai Kaibao's research and development expenses in 2021 will be 73196 million yuan, a year-on-year increase of 317%, mainly due to the increase in investment in research and development activiti.
In 2021, the company has 450 R&D personn.
Although it has changed by -26% compared with the previous year, the proportion will reach 342%, exceeding 266% of the previous ye.
The company will continue to promote the process of research and development projects in 202 First, it will continue to promote the secondary development of its main product Tanreqing and the research and development progress of a series of varieties and products under research; Jointly develop new products in the direction of chiral materials used in medical devices and pharmaceuticals and other related fields, and deepen the company's industry-university-research cooperati.
According to public information, Shanghai Kaibao is a comprehensive pharmaceutical enterprise mainly engaged in the research and development, production and sales of modern Chinese medicin.
It is a national demonstration project base for high-tech industrialization of modern Chinese medicin.
Demonstration enterprise, Shanghai smart facto.
The 2021 annual report shows that the company has always adhered to the road of scientific and technological innovation that combines production, education and resear.
It has two platforms, the Shanghai Enterprise Technology Center and the Academician Expert Workstati.
While continuously improving the level of independent research and development, it has been jointly established with the Medical Experiment Center of the Chinese Academy of Chinese Medical Scienc.
Academician Workstation, and Shanghai Jiaotong University jointly build a biomaterials joint R&D center to build a high-tech platform with strong R&D and production capabilities for rapid transformation of results; at the same time, the company's "Modern Chinese Medicine Product Construction Project R&D Building" is built for future scientific researche.
The introduction and research and development of new products provide basic guarantees, and have a positive role in promoting the company's implementation of innovation and developme.
Zhongsheng Pharmaceutical's R&D expenses in 2021 will be 136 million yuan, a year-on-year increase of 23
During the reporting period, there were 450 R&D personnel, a slight increase of 45% over the previous ye.
The number of R&D personnel in 2021 accounted for 291%, compared with 276% of the previous ye.
has declin.
It is reported that the company has established a multi-mode virtuous cycle of R&D ecosystem, built a R&D model based on independent R&D and effectively supplemented by cooperative R&D, to meet the unmet major clinical needs as the guide, supplemented by product introduction, strategic investment, industrial Mergers and acquisitions, joint ventures and joint development and other forms to achieve synergy between production and research, mutual benefit and win-win situati.
Focusing on the research and development of innovative drugs, the company accurately determines the research and development direction, scientifically and rigorously establishes projects, and integrates internal and external professional resources to implement developme.
The company has established a well-trained and strong executive R&D team covering a complete chain from project initiation, chemical synthesis, biological evaluation, analytical methodology development, formulation research, and drug clinical research, while making appropriate use of social CRO resources , Guarantee quality, quantity, and progress on time, and established a good project management mechani.
The company has established close scientific research cooperation relationships with universities and scientific research institutes such as Sun Yat-sen University, Sichuan University, and National Respiratory Disease Clinical Research Center, and has carried out in-depth industry-university-research cooperation in personnel training, scientific research achievement transformation, and technical suppo.
The company provides external expert think tank support, and constantly transforms socialized scientific research strength into the company's innovation pow.
According to the data, the company is an enterprise integrating drug research and development, production and sales based on ophthalmology, cardiovascular and cerebrovascular, respiratory, digestive and other therapeutic fiel.
In addition, Tailong Pharmaceutical will have 473 R&D personnel in 2021, accounting for 241% of the company's total; Huashen Technology will have 137 R&D personnel in 2021, accounting for 217% of the company's tot.
In general, the proportion of R&D personnel in the total number of Chinese medicine companies still needs to be improved, and the R&D efforts also need to be increased in order to improve the company's own core competitiveness and innovation capabilities and embrace the market opportunities brought about by favorable polici.
Click to enter the exhibition page
